NCT02812394View on ClinicalTrials.gov

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2016

Conditions
Parkinson Disease
Interventions
DRUG

CVT-301 (Dose Level 1)

All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.

DRUG

CVT-301 (Dose Level 2)

All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.

DRUG

Sinemet®

All subjects will receive carbidopa/levodopa tablets administered every 8 hours.

Trial Locations (1)

75247

Site #001, Dallas

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY

NCT02812394 - A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets | Biotech Hunter | Biotech Hunter